What are the most valued startups in the longevity market?

Last updated: 13 March 2026

Download our beautiful pitch about the longevity market

market research pitch 2026 statistics longevity market

In our longevity market deck, you will find everything you need to understand the market

This is a living ranking of the top startups in the longevity market, sorted by their current or estimated valuation.

We built this list to give founders, investors, and analysts a clear, data-backed snapshot of where value is concentrated across the longevity startup ecosystem.

We update this list every month, so bookmark this page if you want to stay on top of how valuations are shifting across the longevity market.

And if you want to better understand this new industry, you can download our pitch covering the longevity market.

A quick summary table

Most valuable longevity startup	Oura ($11.0B)
Second most valuable longevity startup	Retro Biosciences ($4.5B–$5.5B)
Median longevity startup valuation	~$75M
Share of total valuation held by the top 10	~71%
Top longevity startup valuation vs. median	~147x
Median valuation-to-capital-raised ratio	~3.5x
Longevity startups valued at $1B+	7

market map chart top companies startups longevity market

In our longevity market deck, we will give you useful market maps and grids

Top startups in the longevity market ranked by valuation

Here is an updated table that ranks the top startups in the longevity market based on their latest reported or estimated valuations.

If you want more detaild about their fundraising activity, you can check our list of the startups who have raised the most funding in the longevity market.

#	Startup Name	What They Do	Current Valuation ($)	Valuation Confidence Level	Valuation Type	Evidence Status	Total Funding ($)	Funding Confidence Level
1	Oura	Smart health-tracking ring	$11.0B	Full Confidence	Announced Private Round Valuation	Observed	$1.2B	Partial Confidence
2	Retro Biosciences	Longevity therapeutics for age reversal	$4.5B–$5.5B	Partial Confidence	Active Raise Valuation	Estimated	$1.2B	Strong Confidence
3	Insilico Medicine	AI-driven drug discovery platform	$4.1B	Full Confidence	Public Market Cap	Observed	$688M	Strong Confidence
4	Altos Labs	Cellular rejuvenation therapeutics	$3.2B–$4.8B	Partial Confidence	Proxy-Based Estimate	Estimated	$3.0B	Strong Confidence
5	Function Health	Preventive labs and health AI	$2.5B	Full Confidence	Announced Private Round Valuation	Observed	$351M	Strong Confidence
6	Calico Life Sciences	Aging biology drug discovery	$1.5B–$3.0B	Low Confidence	Proxy-Based Estimate	Estimated	N/A	N/A
7	Neko Health	Preventive body-scan health centers	$1.8B–$2.1B	Strong Confidence	Announced Private Round Valuation	Estimated	$325M	Full Confidence
8	Loyal	Longevity drugs for dogs	$800M–$1.1B	Strong Confidence	Implied Valuation from Raise	Implied	$205M	Partial Confidence
9	NewLimit	Epigenetic reprogramming medicines	$810M–$950M	Strong Confidence	Announced Private Round Valuation	Estimated	$280M	Full Confidence
10	Alzheon	Oral Alzheimer's disease therapy	$750M–$950M	Partial Confidence	Proxy-Based Estimate	Estimated	$160M	Partial Confidence
11	Life Biosciences	Rejuvenation gene therapies	$600M–$900M	Partial Confidence	Comparables-Based Estimate	Estimated	$157M	Strong Confidence
12	Juvenescence	Longevity drug development platform	$650M–$850M	Partial Confidence	Implied Valuation from Raise	Implied	$283M	Partial Confidence
13	BioSplice Therapeutics	Alternative-splicing disease therapeutics	$500M–$800M	Partial Confidence	Comparables-Based Estimate	Estimated	$778M	Strong Confidence
14	Timeline	Longevity supplements and skin health	$500M–$750M	Partial Confidence	Implied Valuation from Raise	Estimated	$75M	Strong Confidence
15	Rejuveron Life Sciences	Longevity therapeutics platform	$450M–$700M	Partial Confidence	Implied Valuation from Raise	Estimated	$76M	Partial Confidence
16	Aeovian Pharmaceuticals	Selective mTORC1 small-molecule biotech	$370M–$690M	Strong Confidence	Implied Valuation from Raise	Implied	$142M	Full Confidence
17	Corsera Health	Cardiovascular prevention therapeutics	$450M–$600M	Strong Confidence	Implied Valuation from Raise	Implied	$80M	Full Confidence
18	SciNeuro Pharmaceuticals	Neurodegenerative disease therapeutics	$350M–$660M	Strong Confidence	Implied Valuation from Raise	Implied	$153M	Full Confidence
19	Nura Bio	Neuroprotective small-molecule drugs	$380M–$520M	Partial Confidence	Implied Valuation from Raise	Implied	$141M	Full Confidence
20	Illimis Therapeutics	Neuroinflammation fusion-protein therapeutics	$280M–$525M	Partial Confidence	Implied Valuation from Raise	Implied	$64M	Partial Confidence
21	Nuritas	AI-discovered peptide ingredients	$320M–$430M	Strong Confidence	Implied Valuation from Raise	Implied	$110M	Full Confidence
22	Cambrian Bio	Healthspan-focused therapeutics platform	$300M–$450M	Partial Confidence	Comparables-Based Estimate	Estimated	$188M	Partial Confidence
23	Gordian Biotechnology	In vivo aging drug discovery	$300M–$420M	Partial Confidence	Proxy-Based Estimate	Estimated	$60M	Partial Confidence
24	Viome Life Sciences	Microbiome diagnostics and nutrition	$250M–$400M	Partial Confidence	Revenue or ARR Multiple Estimate	Estimated	$243M	Full Confidence
25	L-Nutra	Longevity nutrition and fasting products	$280M–$360M	Strong Confidence	Implied Valuation from Raise	Implied	$84M	Partial Confidence
26	Biograph	Preventive longevity diagnostics clinics	$240M–$360M	Partial Confidence	Proxy-Based Estimate	Estimated	$54M	Partial Confidence
27	Rubedo Life Sciences	Senolytic therapies for aging diseases	$220M–$320M	Strong Confidence	Implied Valuation from Raise	Estimated	$52M	Full Confidence
28	Blueprint	Consumer longevity products platform	$220M–$320M	Partial Confidence	Implied Valuation from Raise	Implied	$60M	Partial Confidence
29	Cellular Origins	Cell-therapy manufacturing automation	$200M–$330M	Strong Confidence	Implied Valuation from Raise	Implied	$40M	Full Confidence
30	Neurable	Brain-computer interface wearables	$200M–$270M	Strong Confidence	Implied Valuation from Raise	Implied	$56M	Strong Confidence
31	Jocasta Neuroscience	Klotho therapies for cognition	$190M–$260M	Strong Confidence	Implied Valuation from Raise	Implied	$35M	Full Confidence
32	BioAge Labs	Aging-targeted obesity therapeutics	$211M	Full Confidence	Public Market Cap	Observed	$491M	Strong Confidence
33	Human Longevity	Longevity clinics and diagnostics	$170M–$220M	Strong Confidence	Proxy-Based Estimate	Estimated	$380M	Partial Confidence
34	Minovia Therapeutics	Mitochondrial cell therapies	$160M–$220M	Partial Confidence	IPO or Listing Range Valuation	Estimated	$350K	Partial Confidence
35	Elevian	Regenerative protein medicines	$150M–$220M	Partial Confidence	Comparables-Based Estimate	Estimated	$61M	Full Confidence
36	Fountain Life	Longevity clinics and diagnostics	$140M–$210M	Partial Confidence	Implied Valuation from Raise	Implied	$113M	Partial Confidence
37	Turn Biotechnologies	mRNA epigenetic reprogramming therapies	$130M–$220M	Partial Confidence	Implied Valuation from Raise	Estimated	$29M	Partial Confidence
38	resTORbio	mTOR aging therapeutics	$170M	Full Confidence	Acquisition Value	Observed	$163M	Full Confidence
39	Amplifier Therapeutics	AMPK drugs for aging diseases	$120M–$220M	Partial Confidence	Comparables-Based Estimate	Estimated	$33M	Strong Confidence
40	Gero	AI aging drug discovery	$120M–$200M	Partial Confidence	Proxy-Based Estimate	Estimated	$8M	Partial Confidence
41	Alkahest	Plasma-based aging therapeutics	$146M	Full Confidence	Acquisition Value	Observed	$41M	Strong Confidence
42	LyGenesis	Lymph-node organ regeneration therapy	$110M–$160M	Strong Confidence	Implied Valuation from Raise	Implied	$40M	Partial Confidence
43	Neuraly	Neurodegeneration therapeutics platform	$90M–$150M	Partial Confidence	Comparables-Based Estimate	Estimated	$36M	Partial Confidence
44	Liom	Noninvasive biomarker wearable	$90M–$125M	Strong Confidence	Implied Valuation from Raise	Implied	$59M	Partial Confidence
45	Tolerance Bio	Thymus-based immune therapies	$80M–$120M	Strong Confidence	Implied Valuation from Raise	Implied	$20M	Full Confidence
46	Oisin Biotechnologies	Genetic medicines for aging diseases	$80M–$110M	Partial Confidence	Implied Valuation from Raise	Implied	$25M	Partial Confidence
47	Arda Therapeutics	Targeted cell depletion therapies	$75M–$95M	Strong Confidence	Implied Valuation from Raise	Implied	$43M	Full Confidence
48	Shift Bioscience	AI cell rejuvenation discovery	$70M–$95M	Partial Confidence	Implied Valuation from Raise	Implied	$18M	Partial Confidence
49	Radar Therapeutics	RNA-sensing programmable medicines	$60M–$100M	Strong Confidence	Implied Valuation from Raise	Implied	$13M	Full Confidence
50	Everlab	AI preventive longevity healthcare	$60M–$90M	Partial Confidence	Implied Valuation from Raise	Implied	$12M	Full Confidence
51	Acorn Biolabs	Cell preservation for future therapies	$55M–$90M	Strong Confidence	Implied Valuation from Raise	Implied	$12M	Strong Confidence
52	Vasa Therapeutics	Cardiovascular aging therapeutics	$55M–$90M	Partial Confidence	Implied Valuation from Raise	Estimated	$11M	Strong Confidence
53	Booster Therapeutics	Proteasome activator medicines	$60M–$85M	Partial Confidence	Implied Valuation from Raise	Implied	$15M	Full Confidence
54	Thymmune Therapeutics	Thymic cell immune therapies	$50M–$90M	Partial Confidence	Proxy-Based Estimate	Estimated	$7M	Strong Confidence
55	Circulate Health	Therapeutic plasma exchange longevity	$55M–$85M	Strong Confidence	Implied Valuation from Raise	Implied	$12M	Full Confidence
56	MindImmune Therapeutics	Neuroinflammation drugs for Alzheimer's	$50M–$85M	Partial Confidence	Implied Valuation from Raise	Implied	$24M	Partial Confidence
57	Grey Matter Neurosciences	Ultrasound therapies for brain aging	$55M–$80M	Partial Confidence	Implied Valuation from Raise	Implied	$14M	Full Confidence
58	Amphix Bio	Regenerative peptide therapeutics	$50M–$80M	Strong Confidence	Implied Valuation from Raise	Implied	$13M	Partial Confidence
59	AgelessRx	Longevity telehealth prescriptions	$40M–$80M	Partial Confidence	Revenue or ARR Multiple Estimate	Estimated	$4M	Partial Confidence
60	Tally Health	Epigenetic age testing	$45M–$75M	Partial Confidence	Comparables-Based Estimate	Estimated	$10M	Full Confidence
61	Cirrus Therapeutics	Ocular gene and cell therapies	$44M–$73M	Strong Confidence	Implied Valuation from Raise	Implied	$11M	Full Confidence
62	Generation Lab	Biological-age diagnostics platform	$44M–$73M	Partial Confidence	Implied Valuation from Raise	Implied	$15M	Partial Confidence
63	Celularity	Placenta-derived cell therapies	$55M	Full Confidence	Public Market Cap	Observed	$396M	Partial Confidence
64	Epiterna	Longevity therapies for pets	$40M–$70M	Partial Confidence	Comparables-Based Estimate	Estimated	$11M	Full Confidence
65	Junevity	siRNA cell-reprogramming therapeutics	$40M–$67M	Partial Confidence	Implied Valuation from Raise	Implied	$20M	Full Confidence
66	Rejuvenate Bio	Gene therapies for chronic diseases	$35M–$65M	Low Confidence	Comparables-Based Estimate	Estimated	$15M	Strong Confidence
67	Rejuvenation Technologies	Telomere-lengthening mRNA therapeutics	$35M–$60M	Partial Confidence	Proxy-Based Estimate	Estimated	$11M	Full Confidence
68	SENISCA	RNA-based senotherapeutics	$35M–$60M	Partial Confidence	Implied Valuation from Raise	Estimated	$7M	Strong Confidence
69	GlycanAge	Glycan-based biological age testing	$35M–$60M	Low Confidence	Comparables-Based Estimate	Estimated	$4M	Full Confidence
70	Repair Biotechnologies	Cholesterol-clearing aging therapeutics	$35M–$60M	Partial Confidence	Comparables-Based Estimate	Estimated	$11M	Partial Confidence
71	Elysium Health	Consumer longevity supplements	$35M–$55M	Low Confidence	Revenue or ARR Multiple Estimate	Estimated	$60M	Partial Confidence
72	Morphoceuticals	Bioelectric regenerative medicine	$30M–$55M	Partial Confidence	Comparables-Based Estimate	Estimated	$13M	Strong Confidence
73	MitoRx Therapeutics	Mitochondrial obesity therapeutics	$35M–$50M	Strong Confidence	Implied Valuation from Raise	Implied	$12M	Strong Confidence
74	Cyclarity Therapeutics	Atherosclerosis-root-cause therapeutics	$35M–$45M	Strong Confidence	Implied Valuation from Raise	Implied	$24M	Full Confidence
75	Matter Bio	Genome integrity longevity therapeutics	$30M–$50M	Partial Confidence	Implied Valuation from Raise	Implied	$7M	Partial Confidence
76	Cyclana Bio	Endometriosis tissue-discovery biotech	$27M–$45M	Strong Confidence	Implied Valuation from Raise	Implied	$7M	Full Confidence
77	Modulo Bio	Neuroimmune degeneration therapeutics	$27M–$39M	Strong Confidence	Implied Valuation from Raise	Implied	$19M	Strong Confidence
78	clock.bio	Rejuvenation biology drug discovery	$25M–$40M	Partial Confidence	Implied Valuation from Raise	Implied	$9M	Partial Confidence
79	Tomorrow Bio	Human cryonics and biostasis	$25M–$40M	Partial Confidence	Implied Valuation from Raise	Implied	$6M	Strong Confidence
80	NOVOS	Longevity supplements and testing	$20M–$40M	Partial Confidence	Proxy-Based Estimate	Estimated	$3M	Partial Confidence
81	Vincere Biosciences	Parkinson's mitochondrial therapeutics	$20M–$40M	Low Confidence	Proxy-Based Estimate	Estimated	$0M	Low Confidence
82	Biolytica	AI longevity clinic software	$20M–$35M	Partial Confidence	Comparables-Based Estimate	Estimated	$6M	Full Confidence
83	Biopeak	Longevity clinics and optimization	$18M–$32M	Partial Confidence	Implied Valuation from Raise	Implied	$8M	Partial Confidence
84	Deciduous Therapeutics	Senescent-cell clearing immunotherapies	$18M–$32M	Partial Confidence	Comparables-Based Estimate	Estimated	$6M	Partial Confidence
85	NaNotics	Subtractive nanoparticles for disease	$18M–$30M	Partial Confidence	Implied Valuation from Raise	Implied	$10M	Partial Confidence
86	NADMED	NAD metabolite diagnostic testing	$18M–$28M	Partial Confidence	Implied Valuation from Raise	Implied	$4M	Full Confidence
87	Bionic Health	Preventive care clinic platform	$10M–$25M	Low Confidence	Comparables-Based Estimate	Estimated	$3M	Full Confidence
88	Longevica	Longevity therapeutics platform	$12M–$22M	Low Confidence	Proxy-Based Estimate	Estimated	$16M	Partial Confidence
89	Mito Health	AI preventive health platform	$12M–$20M	Strong Confidence	Implied Valuation from Raise	Implied	$4M	Partial Confidence
90	BE Therapeutics	Brain tissue replacement biotech	$8M–$20M	Low Confidence	Proxy-Based Estimate	Estimated	N/A	N/A
91	Edifice Health	Immune-age diagnostics	$10M–$18M	Low Confidence	Proxy-Based Estimate	Estimated	$14M	Strong Confidence
92	Leucadia Therapeutics	Alzheimer's device-based therapy	$8M–$15M	Low Confidence	Proxy-Based Estimate	Estimated	$2M	Partial Confidence
93	Genflow Biosciences	Gene therapies for longevity	$12M	Full Confidence	Public Market Cap	Observed	$6M	Strong Confidence
94	ImmuneAge Bio	Immune rejuvenation drug discovery	$8M–$14M	Partial Confidence	Implied Valuation from Raise	Implied	$2M	Partial Confidence
95	Decode Age	Longevity tests and supplements	$8M–$12M	Partial Confidence	Revenue or ARR Multiple Estimate	Estimated	$2M	Partial Confidence
96	Deep Longevity	AI biological-age analytics	$4M	Full Confidence	Acquisition Value	Observed	N/A	N/A
97	Unity Biotechnology	Senolytic aging therapeutics	$3M	Full Confidence	Public Market Cap	Observed	$200M	Full Confidence
98	LinkGevity	Anti-necrosis longevity therapeutics	$1M–$3M	Low Confidence	Proxy-Based Estimate	Estimated	N/A	N/A
99	CohBar	Mitochondria-based therapeutics company	$0M–$2M	Partial Confidence	Proxy-Based Estimate	Estimated	$65M	Partial Confidence

In our longevity market deck, we provide the data and the context to understand it

Key valuation trends in the longevity market

Insights

Publicly traded longevity companies span a 3,600x valuation range (from Unity Biotechnology at $3M to Oura at $11B), showing just how wide the gap can get even within one sector.
The three highest private-round valuations in the longevity market (Oura, Function Health, Neko Health) all belong to consumer-facing health platforms, not traditional drug developers, which signals a strong investor preference for scalable, non-pharma longevity models.
Epigenetic reprogramming is the best-valued therapeutic modality per dollar raised in the longevity space: NewLimit sits at $810M to $950M on $280M, and Altos Labs reaches $3.2B to $4.8B on $3.0B.
Among longevity acquisition exits with full confidence data, Alkahest returned roughly 3.6x on $41M invested while resTORbio returned approximately 1.0x on $163M, a clear reminder that capital efficiency matters more than total capital raised.
BioAge Labs trades at a $211M public market cap against $491M in total funding, meaning the longevity biotech's current equity value sits at about 43% of invested capital.
Unity Biotechnology's $3M market cap against $200M in total funding represents roughly 98.5% capital destruction, the most extreme case in the entire longevity startup dataset.
Among the 30 longevity startups where both valuation and funding carry full or strong confidence, the median valuation-to-funding multiple is approximately 3.5x, which provides a useful benchmark for private longevity-sector markups.
Nuritas is the only ingredients and food-tech longevity company valued above $300M with strong confidence, suggesting that AI-discovered bioactive peptides occupy a differentiated niche that investors value separately from supplements or diagnostics.

In our longevity market deck, we identify repeatable patterns you can use if you’re building in this market

A few word about our methodology

As you can see, we built a database that ranks startups in the longevity market based on their current valuation.

Estimating longevity startup valuations is not always straightforward. Many companies in this space do not publicly disclose their valuation, and the available information can vary widely depending on the company and its stage.

To build this ranking, we applied a structured valuation methodology and cross-checked information across multiple reliable sources.

Whenever possible, we relied on direct disclosures. These include announced valuations from completed funding rounds, public filings for listed longevity companies, or official acquisition prices.

When a longevity startup is publicly listed, we use its current market capitalization as the reference valuation.

If a company was acquired and no independent valuation can reasonably be estimated today, we use the acquisition price as the main reference point.

When a longevity startup recently raised capital but the valuation was not disclosed, we estimate the implied valuation using typical dilution levels for that stage of fundraising.

In some cases, we also estimate valuations using operating metrics such as revenue, ARR, or customer traction, combined with valuation multiples from comparable companies in the longevity market.

When direct financial data is not available, we may rely on carefully selected comparable startups and other signals such as hiring growth, investor quality, or product traction.

All estimates follow a strict evidence hierarchy. Recent funding rounds with announced valuations carry the most weight, followed by strong operating metrics and comparable company analysis.

We also carefully evaluate the age of every data point. Recent information carries more weight, while older data is treated cautiously and adjusted conservatively when necessary.

Whenever information is uncertain or incomplete, we clearly distinguish between confirmed facts and reasonable inferences.

Because valuation data is not always fully public, each longevity startup in the ranking is assigned a confidence level based on the reliability, recency, and consistency of the available evidence.

Full confidence means the valuation is supported by strong and recent evidence. Strong confidence means the estimate is well supported but includes minor inference. Partial confidence means the estimate relies more heavily on indirect signals. Low confidence means available information is limited or inconsistent.

When confidence is lower, we take a more conservative approach by widening the valuation range. This helps reflect the uncertainty and increases the probability that the true valuation falls within the estimated range.

This reflects how we conduct all our research, including the work behind our report covering the longevity market.

In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.

If you want the full detail on a specific valuation estimate, feel free to contact us and we will gladly explain.

Finally, know that we update the dataset once per month, so come back here if you need fresh information.

In our longevity market deck, we answer all the common questions from investors and entrepreneurs

Related blog posts

- The most recent news in the longevity market

- The most recent funding news in the longevity market

- The latest developments shaping the longevity market

- The evolution of funding activity in the longevity market

- The main fundraising trends in the longevity market

- How large is the longevity market in reality?

- The full range of business models in the longevity market

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.

Back to blog